Advertisement
FDA Alert
FDA Alert
09/28/2023
The FDA approved the second over-the-counter nasal spray with the goal of increasing access to products that can rapidly reverse the effects of opioid overdose.
09/28/2023
FDA Alert
FDA Alert
08/01/2023

Jessica Ganga

Jessica Ganga
The FDA has approved a new buprenorphine treatment option for people with opioid use disorder following clinical trials that tested its safety and efficacy.
08/01/2023
FDA Roundup
FDA Roundup
06/13/2023
This FDA Roundup includes an at-a-glance look at the latest FDA drug approvals in April and May, including treatment for menopausal hot flashes, Clostridioides difficile infection, suspected opioid...
06/13/2023
FDA Alert
FDA Alert
05/27/2023

Jessica Ganga

Jessica Ganga
The FDA’s approval of nalmefene hydrochloride nasal spray marks the first of its kind for health care and community use.
05/27/2023
FDA Alerts
FDA Alerts
04/03/2023

Jessica Ganga

Jessica Ganga
The FDA approves the overdose medication for over-the-counter use after data supports its safe use.
04/03/2023
opioid
opioid
06/15/2018
In an effort to improve access to prevention and treatment for opioid dependence, the FDA has prioritized the approval of generic versions of medication-assisted treatment options.
06/15/2018
Opioid addiction
Opioid addiction
03/29/2018
The FDA’s Psychopharmacologic Drugs Advisory Committee recently reviewed and voted on whether to recommend lofexidine, a non-opioid drug, for the management of opioid withdrawal.
03/29/2018
opioid
opioid
06/09/2017
After careful consideration, the FDA has requested that a particular opioid analgesic be removed from the market.
06/09/2017
opioid
opioid
01/18/2017
The FDA approved Vantrela ER tablets for the management of severe pain requiring daily opioid treatment which alternative treatment options have proven inadequate.
01/18/2017
opioid
opioid
01/10/2017
The FDA has approved a long-acting opioid painkiller designed to be difficult to crush, manipulate, and abuse.
01/10/2017